

Oakridge International Limited

Appendix 4D Half Year Report ended 31 December 2025

Results for announcement to the market

Results	Movements			31 December 2025 \$	31 December 2024 \$
Revenue from ordinary activities	up	61.9%	to	1,789,640	1,105,357
Profit/(loss) from ordinary activities after tax	up	235.7%	to	172,239	(126,968)
Profit/(loss) for the period attributable to the shareholders	up	235.7%	to	172,239	(126,968)
From continuing activities:					
Revenue from continuing activities	up	61.9%	to	1,789,640	1,105,357
Profit/(loss) from continuing activities after tax	up	235.7%	to	172,239	(126,968)
Profit/(loss) from continuing activities attributable to the shareholders	up	235.7%	to	172,239	(126,968)
Net tangible asset backing				Cents	Cents
<i>Per ordinary security (cents per share)</i>				3.98	3.35

Dividends payable

The Directors do not propose or recommend the payment of a dividend.

Control gained over entities having a material effect

Nil

Loss of control of entities having a material effect

Nil.

Detail of associates and joint venture entities

Nil

Oakridge International Limited

ABN 89 122 203 196

Interim Financial Report for the half financial year ended 31 December 2025

Oakridge International Limited

Interim Financial Report – Half-Year Ended 31 December 2025

Contents

Directors' Report.....	4
Auditors Independence Declaration.....	6
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income.....	7
Condensed Consolidated Statement of Financial Position.....	8
Condensed Consolidated Statement of Changes in Equity.....	9
Condensed Consolidated Statement of Cash Flows	10
Notes to the Financial Statements.....	11
Directors' Declaration	18
Independent Auditor's Review Report to the Members of Oakridge International Limited	19

This interim financial report does not include all of the notes and other disclosure information of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the Annual Report for the financial year ended 30 June 2025 and any public announcements made by Oakridge International Limited during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

Corporate directory

Directors	Mr. Con Unerkov (Executive Chairman and director) Mr. Peter Whelan (Non-executive director) Mr. Wally Pastuch (Non-executive director)
Company secretary	Ms. Julie Edwards
Registered office in Australia	Suite 3, Level 3, 89 Pirie Street Adelaide, SA 5000
Principal office in Australia	Suite 3, Level 3, 89 Pirie Street Adelaide, SA 5000
Share registry	Link Market Services Tower 4, 727 Collins Street Melbourne Vic 3008
Auditor	Moore Australia Audit (Vic) Level 44 600 Bourke Street Melbourne, Victoria, 3000
Stock exchange listing	Australian Securities Exchange Ltd OAK - listed ordinary shares
Website address	www.oakridgeint.com

Directors' Report

The directors present their report on Oakridge International Limited (the "Company" or "Oakridge") and the entities it controlled ("the Group") at the end of, or during, the half-year ended 31 December 2025.

Directors

The following persons were directors of Oakridge during the half-year under review and up to the date of this report, unless otherwise stated:

Mr. Con Unerkov	Executive Chairman and director
Mr. Peter Whelan	Non-executive director
Mr. Wally Pastuch	Non-executive director

Company secretary

Mrs. Julie Edwards

Principal activities

The Group is engaged in the business of selling professional healthcare technology equipment and solutions to healthcare facilities. It develops and distributes its own range of nurse call hardware and software solutions for use across multiple healthcare sectors, including hospitals, aged care, disability care and supported independent living. The business has recently focused on expanding into assisted independent living technologies, utilising synergies with our Internet of Things (IoT) platform.

Oakridge continues to seek opportunities to expand its business and revenue base by exploring emerging opportunities in technology sectors focused on IoT and healthcare.

There were no significant changes in the nature of its activities during the period, nor were there any significant changes in the state of its affairs.

Dividends

The directors recommend that no dividend be paid or declared at this point in time. No amounts have been paid or declared by way of dividend during the half-year period under review.

Review and results of operations

The profit from ordinary activities after tax for the half-year increased 235.70% to \$172,239 (2024: loss of \$126,968) on the back of sustained momentum in sales activity, project delivery and technology development. Revenue from ordinary activities for the half-year increased 61.9% to \$1,789,640 (2024: \$1,105,357).

The following provides a summary of the Group's activities and achievements during the course of the half year:

Sales Activity

The Group maintained strong installation and project activity across multiple major sites, with systems now operational over several deployment stages and consistent order flow from customers and distribution partners.

A robust pipeline of quotes and tenders has been established, supporting a positive outlook for FY2026 project conversions and collaboration with key property and care providers continued across a portfolio of healthcare projects, including assisted living initiatives delivered via the NuCaMS platform.

Product Development

Product development remained a core focus, with enhancements to the NuCaMS and NuCaMS Enterprise platforms, including improved reporting, scalability and performance.

RTLS capability integration progressed, updated LED and LCD display modules were finalised and the product roadmap continued to align with the evolving AS8311:2024 Nurse Call Standard, supporting compliance and competitive positioning.

Cloud-based integrations with Microsoft Azure for Single Sign-On were validated, enabling scalable enterprise deployments across multiple client networks.

Directors' Report (continued)

Business Development and Operations

Strategic partner relationships strengthened across all states, with distribution discussions progressing to expand nationwide coverage and coordinated forecasting and planning improving delivery timelines and stock visibility.

Brand visibility increased through digital outreach and social channel engagement, contributing to additional inbound enquiries and project leads, while industry research initiatives provided a clearer view of the competitive landscape and supported future market differentiation.

Operationally, adoption of Zoho Books and associated inventory platforms progressed, improving internal communications, data consistency and alignment between operations and financial control.

Prospects

The Group will continuously monitor its overhead costs and cashflow, continue to look at strengthening its capital base and seek strategic partners to further develop its business.

The Group has strengthened its position in the healthcare technology sector, underpinned by a proven track record of project delivery, an integrated product suite spanning nurse call and assistive technologies and enterprise infrastructure supporting scalable deployments.

As a result the Group enters the second half of FY2026 with considerable operational momentum and a robust pipeline of quotes and orders, with several new project opportunities expected from strengthened industry partnerships. The existing project pipeline and anticipated conversion of inventory investment to revenue provide a strong foundation for continued growth.

Health, safety, environment, and community

During the half-year under review, there were no reportable incidents relating to health, safety, or community-related matters.

No business objective will take priority over the Occupational Health and Safety Policy and the Company's record of achievement in this important area of its activities will form an essential part of the measure of its overall success.

Events occurring after balance sheet date

Other than as disclosed in notes to the financial statements, there has not arisen in the interval between the end of the financial year and the date of the report any matter or circumstance that has significantly affected, or may significantly affect the Group's operations, results or the state of affairs in future financial years.


Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out on page 6.

Rounding of amounts

The Company is of a kind referred to in ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191, relating to the "rounding" of amounts in the directors' report and financial report. The Company has rounded amounts in the directors' report and financial report to the nearest dollar, in accordance with that instrument.

This report is made in accordance with a resolution of directors.



Mr. Con Unerkov
Chairman

Adelaide, South Australia

11 February 2026

Moore Australia**VICTORIA**

Level 44, 600 Bourke Street
Melbourne VIC 3000
T +61 3 9608 0100

Level 3, 237 Ryrie Street
Geelong VIC 3220
T +61 3 5215 6800

TASMANIA

Level 3, 63-65 Cameron Street
Launceston TAS 7250
T +61 3 6334 0500

victoria@moore-australia.com.au
www.moore-australia.com.au

AUDITOR'S INDEPENDENCE DECLARATION UNDER S 307C OF THE CORPORATIONS ACT 2001 TO THE DIRECTORS OF OAKRIDGE INTERNATIONAL LIMITED AND CONTROLLED ENTITIES

As auditor for the review of Oakridge International Limited for the half year ended 31 December 2025, I declare that, to the best of my knowledge and belief, there have been:

- i. no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- ii. no contraventions of any applicable code of professional conduct in relation to the audit.



ANDREW JOHNSON
Partner – Audit and Assurance
[Moore Australia Audit \(VIC\)](#)
Melbourne, Victoria
11 February 2026

Moore Australia
Moore Australia Audit (VIC)
ABN 16 847 721 257
Chartered Accountants

Oakridge International Limited
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
For The Half-Year Ended 31 December 2025

		Half-Year to 31 December 2025	31 December 2024
Note		\$	\$
Revenue and other income	3	1,789,640	1,105,357
Cost of Sales; inventories and other cost of sales		(638,514)	(428,410)
Foreign currency gains		(897)	(2,771)
Employee and contracting expense		(477,835)	(301,240)
Professional and legal costs		(70,526)	(44,696)
Depreciation and amortisation expense		(60,633)	(55,846)
Consulting and advisory fees		(30,000)	(90,000)
Occupancy costs		(17,631)	(20,592)
Finance costs		(2,783)	(4,363)
Travel		(16,362)	(11,281)
Marketing and promotion		(20,234)	(22,394)
Directors remuneration		(123,996)	(123,996)
Other expenses		(157,990)	(126,736)
Profit / (Loss) before income tax		172,239	(126,968)
Income tax expense	4	-	-
Profit / (Loss) from continuing operations for the half-year		172,239	(126,968)
Loss from discontinued operations net of income tax		-	-
Total profit / (loss) for the half year		172,239	(126,968)
Other comprehensive income		-	-
Total comprehensive profit / (loss) for the half-year		172,239	(126,968)
Total comprehensive profit / (loss) attributable to:			
Owners of the parent		172,239	(126,968)

Earnings per share for profit / (loss) attributable to the shareholders of the company

	Cents	Cents
Basic and diluted earnings per share	0.64	(0.47)
Diluted earnings per share	0.64	(0.47)

The above condensed consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

Oakridge International Limited
Condensed Consolidated Statement of Financial Position
As at 31 December 2025

	Note	31 December 2025 \$	30 June 2025 \$
ASSETS			
Current assets			
Cash and cash equivalents	5	151,219	468,939
Other financial assets		61,948	61,948
Trade and other receivables		717,332	138,878
Prepayments		466,177	333,132
Inventory		552,026	380,757
Total current assets		1,948,702	1,383,654
Non-current assets			
Plant and equipment		54,709	64,873
Right of use assets		107,125	157,570
Total non-current assets		161,834	222,443
TOTAL ASSETS		2,110,536	1,606,097
LIABILITIES			
Current liabilities			
Trade and other payables		452,347	290,764
Short Term Advance	6	215,000	-
Borrowings		32,548	32,548
Provisions		165,320	157,743
Lease liabilities		104,366	106,488
Unearned revenue		31,586	37,863
Total current liabilities		1,001,167	625,406
Non-current liabilities			
Provisions		21,919	15,540
Lease liabilities		12,965	62,905
Total non-current liabilities		34,884	78,445
TOTAL LIABILITIES		1,036,051	703,851
NET ASSETS		1,074,485	902,246
EQUITY			
Contributed equity	7	29,329,690	29,329,690
Reserves		32,088	32,088
Accumulated losses		(28,287,293)	(28,459,532)
TOTAL EQUITY		1,074,485	902,246

The above condensed consolidated statement of financial position should be read in conjunction with the accompanying notes.

Oakridge International Limited
Condensed Consolidated Statement of Changes in Equity
For the Half-Year Ended 31 December 2025

	Contributed equity	Share option reserve	Accumulated losses	Total
	\$	\$	\$	\$
2025				
Balance at 1 July 2025	29,329,690	32,088	(28,459,532)	902,246
Profit for the half-year	-	-	172,239	172,239
Other comprehensive income	-	-	-	-
Total comprehensive profit for the half-year	-	-	172,239	172,239
Balance at 31 December 2025	29,329,690	32,088	(28,287,293)	1,074,485
2024				
Balance at 1 July 2024	29,329,690	32,088	(28,330,737)	1,031,041
Share issuance to employees	-	-	-	-
Issuance of share options	-	-	-	-
Loss for the half-year	-	-	(126,968)	(126,968)
Other comprehensive income	-	-	-	-
Total comprehensive loss for the half-year	-	-	(126,968)	(126,968)
Balance at 31 December 2024	29,329,690	32,088	(28,457,705)	904,073

The above condensed consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Oakridge International Limited
Condensed Consolidated Statement of Cash Flows
For the Half-Year Ended 31 December 2025

		Half-year to	
		31 December	31 December
		2025	2024
		\$	\$
Note			
Cash flows from operating activities			
	Receipts from customers (inclusive of GST)	1,202,400	820,232
	Interest received	1,612	266
	Interest paid	(2,783)	(4,363)
	Payments to suppliers and employees (inclusive of GST)	(1,681,863)	(1,368,466)
8	Total net cash outflow from operating activities	(480,634)	(552,331)
Cash flows from investing activities			
	Payments for plant and equipment	(24)	(7,914)
	Payment of rental holding facility	-	-
	Proceeds from investment in term deposits	-	2,152
	Total net cash inflow from investing activities	(24)	(5,762)
Cash flows from financing activities			
	Repayment of lease liabilities	(52,062)	(48,518)
	Short Term Advance	215,000	-
	Total net cash outflow from financing activities	162,938	(48,518)
	Net decrease in cash and cash equivalents	(317,720)	(606,611)
	Cash and cash equivalents at the beginning of the half-year	468,939	961,575
5	Cash and cash equivalents at the end of the half-year	151,219	354,964

The above condensed consolidated statement of cash flows should be read in conjunction with the accompanying notes.

1 Significant accounting policies

(a) Basis of preparation

These general purpose condensed financial statements for the interim half-year reporting period ended 31 December 2025 have been prepared in accordance with requirements of the *Corporations Act 2001* and Australian Accounting Standard AASB134 *Interim Financial Reporting*. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS34 *Interim Financial Reporting*.

The Group is a for-profit entity for the purpose of preparing the financial statements. This interim financial report is intended to provide users with an update of the latest half-year financial statements of Oakridge International Limited and its controlled entities (the Group). As such, it does not contain all notes of the type normally included in an annual financial report. The same accounting policies have been applied in the interim financial statements as compared to the most recent annual financial statements for the year ended 30 June 2025. It is therefore recommended that this financial report be read in conjunction with the annual financial report of the Group for the year ended 30 June 2025, together with any public announcements made during the half-year and up to the date of this financial report.

The Group has adopted all the new and revised Standards and Interpretations issued by the Australian Accounting Standards Board that are relevant to its operations and effective for the current reporting period. There was no material impact on the financial report as a result of the adoption of these standards.

(b) Going concern

The consolidated financial statements have been prepared on a going concern basis, which assumes the continuity of normal business activities and the settlement of liabilities in the normal course of business.

During the half-year ended 31 December 2025 the Group's profit after income tax expense amounted to \$172,239 (2024: loss of \$126,968) and cash outflows from operations for the half-year were \$480,634 (2024: \$552,331). Cash outflows from operations have resulted in the reduction of cash reserves of the Group and have the potential to impact the ability of the Group to continue as a going concern.

Notwithstanding this, the directors believe the Group remains a going concern and will continue to be able to pay its debts as and when they fall due. In reaching this conclusion the directors have given regard to:

- the Group has recorded a profit in the 6 months and expects profitability to lead to positive cash flows from operations in future reporting periods; and
- the Group's ability to raise equity and/or capital funding,

The Group's ability to continue to operate as a going concern is dependent upon the items listed above. Should these events not occur as anticipated, the Group may be unable to continue as a going concern and may be required to realise its assets and extinguish its liabilities other than in the ordinary course of business.

(c) Rounding of amounts

The Company is of a kind referred to in ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191, relating to the "rounding" of amounts in the directors' report and financial report. The Company has rounded amounts in the directors' report and financial report to the nearest dollar, in accordance with that instrument.

2 Operating segments

Identification of reportable segments

The Group has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors (chief operating decision makers) in assessing performance and determining the allocation of resources.

Reportable segments disclosed are based on aggregating operating segments where the segments are considered to have similar economic characteristics and meet the other aggregation criteria of AASB 8 *Operating Segments*.

Operating segment are Australian based unless otherwise stated.

Activity by segment

Healthcare technology

JCT Healthcare Pty Ltd ("JCT"), a wholly owned subsidiary of the Company, is a provider of innovative technology solutions for the healthcare sector. JCT develops and distributes its own range of nurse call hardware and software solutions for use across multiple healthcare sectors including hospitals, aged care, disability care and supported independent living.

Technology development

Technology focused on the Internet of Things (IoT) technology.

Geothermal projects

Oakridge held interests in geothermal project(s) in Indonesia:

- Sokoria Geothermal Project, under a Joint Venture with PT Bakrie Power, for a 30 MW geothermal development on Flores Island, Indonesia, with Oakridge holding a 45% interest in the project. On 16 January 2017 KS Orka completed acquisition of Sokoria Geothermal Project. Under the terms of the SPA Oakridge received the nominal amount of US\$1. An additional payment of up to US\$947,368 will become payable within 30 days of KS Orka issuing notification of intent to develop project. This project has been fully impaired. In March 2022, Oakridge received a notification of intent to develop a portion of the project which resulted in a payment from KS Orka of US\$157,939 or \$217,372. In April 2024, Oakridge received a further payment of US\$94,763.80 or approximately \$144,810. Oakridge may receive additional payments if KS Orka commits to further development.

Unallocated

Comprising corporate and overhead costs such as director's fees, listing and share registry fees, acquisitions and associated costs.

2 Operating segments (continued)

(i) Segment performance

	Technology development	Healthcare technology	Geothermal projects	Unallocated	Total
	\$	\$	\$	\$	\$
Half-year ended 31 December 2025:					
Interest revenue	-	-	-	1,612	1,612
Revenue:					
- Over time	-	87,104	-	-	87,104
- At a point in time	-	1,352,340	-	-	1,352,340
Other income	-	-	-	-	-
Sale of Assets	-	200	-	-	200
R and D tax concession	-	262,611	-	85,772	348,383
Total segment revenue	-	1,702,255	-	87,384	1,789,639
Total segment expenses	-	(1,274,419)	(740)	(342,241)	(1,617,400)
Profit / (loss) before income tax for the half-year	-	427,836	(740)	(254,857)	172,239

	Technology development	Healthcare technology	Geothermal projects	Unallocated	Total
	\$	\$	\$	\$	\$
Half-year ended 31 December 2024:					
Interest revenue	-	-	-	266	266
Revenue:					
- Over time	-	27,227	-	-	27,227
- At a point in time	-	875,037	-	-	875,037
Other income	-	-	-	-	-
R and D tax concession	-	202,827	-	-	202,827
Total segment revenue	-	1,105,091	-	266	1,105,357
Total segment expenses	(8,333)	(876,107)	(321)	(347,564)	(1,232,325)
Profit / (loss) before income tax for the half-year	(8,333)	228,984	(321)	(347,298)	(126,968)

(ii) Segment assets and liabilities

	Healthcare technology	Geothermal projects	Unallocated	Eliminations	Total
	\$	\$	\$	\$	\$
As at 31 December 2025:					
Total assets	1,833,971	240	5,231,238	(4,954,913)	2,110,536
Total liabilities	(3,274,823)	(2,167,790)	(548,351)	4,954,913	(1,036,051)
As at 30 June 2025:					
Total assets	1,397,824	240	5,211,071	(5,003,038)	1,606,097
Total liabilities	(3,266,512)	(2,167,050)	(273,327)	5,003,038	(703,851)

3 Revenue and other income

	Half-year to	
	31 December 2025 \$	31 December 2024 \$
<i>Revenue from contracts with customers:</i>		
Revenue recognised at a point in time – sale of goods	1,352,340	875,037
Revenue recognised over time – projects and services	87,104	27,227
	1,439,444	902,264
<i>Other income:</i>		
Interest income	1,612	266
R&D tax concession	348,383	202,827
Other income	200	-
	350,195	203,093
	1,789,639	1,105,357

4 Income Tax

No income tax expense has been recognised for the half-year ended 31 December 2025. The Group continues to utilise carried-forward tax losses and no deferred tax assets have been recognised as the recovery of those losses cannot be regarded as probable at this time, consistent with the Group's historical loss position.

5 Cash and cash equivalents

	31 December 2025 \$	30 June 2025 \$
Cash on hand	-	-
Cash at bank	151,219	468,939
	151,219	468,939

6 Short Term Advance

During the half year, the Company received a short term advance totaling \$215,000 from Montague Capital Pty Ltd, a company associated with a director of the Company, Mr. Con Unerkov.

The advance is interest free and payable on demand.

7 Contributed equity

	31 December 2025 No.	30 June 2025 No.
Ordinary shares – fully paid	26,997,908	26,997,908

(a) Movements in equity

	Half-year to 31 December 2025		Half-year to 31 December 2024	
	No.	\$	No.	\$
Balance at the start of the half-year	26,997,908	29,329,690	26,997,908	29,329,690
Balance at the end of the half-year	26,997,908	29,329,690	26,997,908	29,329,690

(b) Employee Share Option Scheme

The Group did not issue any share options to employees during the half year.

During the 23/24 financial year the Company issued the following stock options to qualified employees.

On 14 November 2023, the Company issued 306,480 unlisted options to its employees which are exercisable at \$0.10 per option and expire on 13 November 2026. As at the balance date and the date of this report, none of the 306,480 unlisted options have been exercised.

On 20 December 2023, the Company issued 599,970 unlisted options exercisable at \$0.10 expiring 19 December 2026 to an entity associated with Con Unerkov, a director of the Company. As at the balance date and the date of this report, none of the 599,970 unlisted options have been exercised.

(c) Options issued during the half year

The Group did not issue any share options during the half year.

In the 23/24 financial year, at a members meeting, the shareholders approved the issuance of 9,398,496 shares at a share price of \$0.0532 and 7,142,857 unlisted options with an exercise price of \$0.07 and an expiry date of 30 June 2026 to Montague Capital Pty Ltd. As at the balance date and the date of this report, none of the 7,142,857 unlisted options have been exercised.

8 Cash flow information

	Half-year to 31 December 2025 \$	31 December 2024 \$
<i>Reconciliation of profit after income tax to net cash inflow/(outflow) from operating activities:</i>		
Profit/(loss) for the half-year	172,239	(126,968)
<u>Non-cash items in profit or loss:</u>		
Depreciation and amortisation expense	60,633	55,846
 <u>Change in operating assets and liabilities:</u>		
(Increase) in trade or other receivables	(578,454)	(274,586)
(Increase) in inventory	(171,268)	(42,974)
(Increase) in other current assets	(133,046)	(153,419)
Increase in trade and other payables	161,583	3,942
(Decrease) in unearned revenue	(6,277)	(7,502)
Increase/(decrease) in provisions	13,956	(6,670)
Net cash outflow from operating activities	(480,634)	(552,331)

9 Contingent liabilities

- (a) On 31 December 2019, Oakridge entered into a Share Placement Agreement (“SPA”) issuing 250 million ordinary shares in the Group at \$0.001 per ordinary share, on a pre consolidated basis, for total proceeds of \$250,000. At the time of this transaction, Mr Con Unerkov was appointed to the Board of the parent company. Pursuant to the SPA, the parent company made certain representations in respect to liabilities in the Group to Teko International Limited, the purchaser. However, in the process of preparing the Group’s accounts for the year ended 30 June 2020, the Group became aware that some of the representations made by the Group were not accurate.

The Company is currently seeking legal advice to determine the extent of its legal liabilities in respect of a potential breach of the SPA. At the date of this report, the Group has not been able to quantify the liability, if any, in respect to these breaches.

- (b) On 1 December 2012, JCT Healthcare Pty Limited (“JCT”), a subsidiary of the Company, received a grant of \$230,000 under a Deed of Grant with Techin SA (formerly Bio Innovation SA) for the development of a web based messaging software licence. The development was completed on 30 June 2013. Pursuant to the Deed of Grant, for a period of 10 years (“Term of the Grant”) the amount of the outstanding loan shall accrue annual indexation fees calculated at the Consumer Price Index on the outstanding loan amount. During this Term of the Grant, JCT is obligated to pay the loan from the royalties calculated on 7% of the income derived from the commercialization of the messaging software. The Deed of Grant terminated on 30 June 2023.

As at 31 December 2025, the current portion of the outstanding loan, inclusive of the accrual annual indexation fees, amounting to \$318,340 (30 June 2025: \$308,323) of which approximately \$32,548 (2023: \$32,548) is payable on the royalties outstanding and payable for the period from 1 July 2019 to 31 December 2024.

The web-based messaging software licence derived no royalty repayments for the six months ended 31 December 2025 (30 June 2025: nil) and it is not expected to derive any material royalty revenue and Loan repayments to the Group in the future. As a result, it is unlikely that JCT will need to repay the Loan amount of \$285,792, including any future annual indexation, as it is not expected to derive any royalty income which is the basis of the Loan repayment. Accordingly, the Company has accounted \$32,548 for the amount of the royalties outstanding and payable as at 31 December 2025 (30 June 2025: \$32,548) in the Borrowings account on the balance sheet. A balance of \$269,434 was accounted for in the Profit and Loss account as a reversal of borrowings in the 2023 financial year, and also disclosed as a contingent liability in the event of certain conditions set out in the Term of the Grant including JCT becoming bankrupted or move out of state of South Australia in the future.

- (c) In March 2023, the Company entered into an agreement to lease a corporate office for a term of four years from 13 March 2023 to 12 March 2027. The Company opened a term deposit which was used as security on a bank guarantee to secure the Company’s obligations under the lease over the Company’s corporate office.
- (d) In November 2023, JCT Healthcare Pty Ltd (“JCT”), a wholly owned subsidiary of the Company, entered into an agreement to lease an office for a term of three years from 15 November 2023 to 14 November 2026. JCT opened a term deposit which was used as security on a bank guarantee to secure the obligations under the lease over JCT’s office.

10 Related party transactions

Other than disclosed below, there were no other transactions with key management personnel other than reimbursement of expenses incurred by them in performing their respective duties.

During the six months period ended 31 December 2025, the Company paid to directors and executive officers total remuneration of \$123,996 (31 December 2024: \$123,996).

During the half year, the Company received a short term advance totaling \$215,000 from Montague Capital Pty Ltd, a company associated with a director of the Company, Mr. Con Unerkov. The advance is interest free and payable on demand.

During the six months ended 31 December 2025, a related party of our Director and CEO, Mr. Unerkov, was paid a fee in addition to statutory superannuation contributions, to perform part-time administrative services for a wholly-owned subsidiary of the Company. The fee was \$4,166.67 per month.

11 Events subsequent to the reporting date

Other than disclosed below, there has been no matter or circumstance, which has arisen since 31 December 2025 that has significantly affected or may significantly affect:

- (a) the operations, in financial periods subsequent to 31 December 2025, of the Group, or
- (b) the results of those operations, or
- (c) the state of affairs, in financial periods subsequent to 31 December 2025, of the Group.

No events have occurred subsequent to 31 December 2025:

12 Comparative Figures

Certain comparative figures have been reclassified to conform to the current period's presentation.

Directors' Declaration

In the directors' opinion:

- (a) the attached financial statements and notes are in accordance with the *Corporations Act 2001*, including:
 - (i) complying with Accounting Standard *AASB 134 Interim Financial Reporting* and the *Corporations Regulations 2001*; and
 - (ii) giving a true and fair view of the Group's financial position as at 31 December 2025 and of its performance for the half-year ended on that date; and
- (b) there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Directors.



Mr. Con Unerkov
Director

11 February 2026

VICTORIA

Level 44, 600 Bourke Street
Melbourne VIC 3000
T +61 3 9608 0100

Level 3, 237 Ryrie Street
Geelong VIC 3220
T +61 3 5215 6800

TASMANIA

Level 3, 63-65 Cameron Street
Launceston TAS 7250
T +61 3 6334 0500

victoria@moore-australia.com.au
www.moore-australia.com.au

INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF OAKRIDGE INTERNATIONAL LIMITED

Report on the Half-Year Financial Report

Conclusion

We have reviewed the accompanying half-year financial report of Oakridge International Ltd (the Company), which comprises the condensed consolidated statement of financial position as at 31 December 2025, the condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of changes in equity, the condensed consolidated statement of cash flows for the half-year ended on that date, notes comprising a summary of material accounting policy information and other explanatory information and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001*, including:

- a. giving a true and fair view of the Group's financial position as at 31 December 2025 and of its performance for the half-year ended on that date; and
- b. complying with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis of Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report.

We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards) (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Responsibility of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Company's financial position as at 31 December 2025 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



ANDREW JOHNSON
Partner – Audit and Assurance
[Moore Australia Audit \(VIC\)](#)
Melbourne, Victoria
11 February 2026

Moore Australia
Moore Australia Audit (VIC)
ABN 16 847 721 257
Chartered Accountants